HUP0100199A2 - Anilid-származékot tartalmazó gyógyászati készítmény CCR5 antagonizálására - Google Patents

Anilid-származékot tartalmazó gyógyászati készítmény CCR5 antagonizálására

Info

Publication number
HUP0100199A2
HUP0100199A2 HU0100199A HUP0100199A HUP0100199A2 HU P0100199 A2 HUP0100199 A2 HU P0100199A2 HU 0100199 A HU0100199 A HU 0100199A HU P0100199 A HUP0100199 A HU P0100199A HU P0100199 A2 HUP0100199 A2 HU P0100199A2
Authority
HU
Hungary
Prior art keywords
optionally substituted
ring
ccr5
pharmaceutical composition
antagonizing
Prior art date
Application number
HU0100199A
Other languages
English (en)
Inventor
Yoshio Aramaki
Masanori Baba
Naoyuki Kanzaki
Ken-Ichi Kuroshima
Osamu Nishimura
Hidekazu Sawada
Mitsuru Shiraishi
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of HUP0100199A2 publication Critical patent/HUP0100199A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/62—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Abstract

A találmány CCR5-antagonizáló gyógyászati kompozícióra vonatkozik,amely egy (I) általános képletű vegyületet vagy annak egy sójáttartalmazza - a képletben R1 jelentése adott esetben szubsztituált 5vagy 6 tagú gyűrű; W jelentése (a) vagy (b) általános képletűkétértékű csoport, ahol az A gyűrű adott esetben szubsztituált 5 vagy6 tagú aromás gyűrű; X jelentése adott esetben szubsztituált szénatom,nitrogénatom vagy oxigénatom; és a B gyűrű adott esetben szubsztituált5-7 tagú gyűrű; Z jelentése vegyi kötés vagy kétértékű csoport; R2jelentése adott esetben szubsztituált aminocsoport, amelyben anitrogénatom kvaterner ammóniumot képezhet. A CCR5-receptornak az AIDSkialakulásában van szerepe. Ó
HU0100199A 1997-12-19 1998-12-17 Anilid-származékot tartalmazó gyógyászati készítmény CCR5 antagonizálására HUP0100199A2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP35148097 1997-12-19
JP21887598 1998-08-03
JP23438898 1998-08-20
PCT/JP1998/005708 WO1999032100A2 (en) 1997-12-19 1998-12-17 Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative

Publications (1)

Publication Number Publication Date
HUP0100199A2 true HUP0100199A2 (hu) 2001-04-28

Family

ID=27330200

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100199A HUP0100199A2 (hu) 1997-12-19 1998-12-17 Anilid-származékot tartalmazó gyógyászati készítmény CCR5 antagonizálására

Country Status (12)

Country Link
US (2) US6172061B1 (hu)
EP (1) EP1039899A2 (hu)
JP (1) JP2000128782A (hu)
KR (1) KR20010032841A (hu)
CN (1) CN1282243A (hu)
AU (1) AU748064B2 (hu)
BR (1) BR9813691A (hu)
CA (1) CA2304959A1 (hu)
HU (1) HUP0100199A2 (hu)
ID (1) ID29994A (hu)
NO (1) NO20003179L (hu)
WO (1) WO1999032100A2 (hu)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
FR2746101B1 (fr) * 1996-03-14 1998-04-30 Composes bicycliques-aromatiques
WO2000006153A1 (en) * 1998-07-28 2000-02-10 Smithkline Beecham Corporation Propenamides as ccr5 modulators
JP2000128842A (ja) * 1998-08-20 2000-05-09 Takeda Chem Ind Ltd ４級アンモニウム塩誘導体およびその用途
AU6123099A (en) * 1998-10-15 2000-05-01 Takeda Chemical Industries Ltd. Process for the preparation of amine derivatives
US6635278B1 (en) * 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
EP1140896A1 (en) * 1998-12-21 2001-10-10 Takeda Chemical Industries, Ltd. Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
JP2003524620A (ja) 1999-03-24 2003-08-19 アノーメッド インコーポレイティド ケモカインレセプター結合複素環化合物
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
CA2373073A1 (en) * 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
EP1184381A4 (en) 1999-05-18 2003-03-12 Takeda Chemical Industries Ltd METHOD FOR PRODUCING 2,3-DIHYDROTHIEPINE DERIVATIVES
EP1186604A4 (en) * 1999-06-16 2002-10-23 Takeda Chemical Industries Ltd BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF
AU6870500A (en) * 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine derivatives
AU6870600A (en) * 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine compounds
GB2371622A (en) * 1999-09-23 2002-07-31 Isis Innovation Susceptibility gene for inflammatory bowel disease
EP1236476A1 (en) * 1999-12-10 2002-09-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
CA2400979A1 (en) * 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Process for producing cyclic compound
IL151475A0 (en) 2000-03-30 2003-04-10 Bristol Myers Squibb Co Beadlets containing stavudine
JP2004508421A (ja) * 2000-09-15 2004-03-18 アノーメッド　インコーポレイティド ケモカインレセプター結合性ヘテロ環式化合物
WO2002034760A2 (en) * 2000-10-23 2002-05-02 Smithkline Beecham Corporation Compounds and methods
WO2002066454A1 (en) * 2001-02-21 2002-08-29 Sankyo Company, Limited Chromene derivatives
AU2002328092A1 (en) * 2001-08-08 2003-02-24 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use as hiv inhibitors
WO2003014110A1 (fr) * 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Derive de benzazepine, son procede de preparation et d'utilisation
KR20040044909A (ko) 2001-09-12 2004-05-31 아노르메드 인코포레이티드 거울상이성체적으로 순수한 아미노-치환된 융합비사이클릭 환의 합성
US20050245537A1 (en) * 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
US8030336B2 (en) * 2002-12-13 2011-10-04 Ym Biosciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
US7288654B2 (en) * 2003-02-07 2007-10-30 Takeda Pharmaceutical Company Ltd Fused-ring pyridine derivative, process for producing the same, and use
BRPI0408332A (pt) * 2003-03-14 2006-03-21 Ono Pharmaceutical Co derivados heterocìclicos contendo nitrogênio e medicamentos contendo os mesmos como ingrediente ativo
CN101333186A (zh) * 2003-03-14 2008-12-31 小野药品工业株式会社 含氮杂环衍生物以及包含所述化合物作为活性成分的药物
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
MX2007000036A (es) * 2004-06-25 2007-05-18 Johnson & Johnson Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
CN101775013A (zh) 2004-09-13 2010-07-14 小野药品工业株式会社 含氮杂环衍生物及含有其作为活性成分的药物
WO2006129679A1 (ja) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
PL1942108T3 (pl) 2005-10-28 2014-03-31 Ono Pharmaceutical Co Związek zawierający grupę zasadową i jego zastosowanie
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
WO2007105637A1 (ja) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US20090186817A1 (en) * 2006-03-21 2009-07-23 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
AR065369A1 (es) * 2007-02-19 2009-06-03 Novartis Ag Derivados de ciclohexil - amida del acido aril- carboxilico
US8168829B2 (en) * 2007-10-26 2012-05-01 Janssen Pharmaceutica N.V. Synthesis of quaternary salt compounds
US8093428B2 (en) * 2007-10-26 2012-01-10 Janssen Pharmaceutica N.V. Synthesis of quaternary salt compounds
CN102796075B (zh) * 2008-01-11 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 苯并环庚烯类衍生物、其制备方法及医药用途
CN101481323B (zh) * 2008-01-11 2013-11-20 中国人民解放军军事医学科学院毒物药物研究所 苯并环庚烯类衍生物、其制备方法及医药用途
ES2705101T3 (es) * 2008-11-06 2019-03-21 Ventirx Pharmaceuticals Inc Métodos de síntesis de derivados de benzazepinas
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2016019587A1 (en) * 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
BR112017013130A2 (pt) 2014-12-23 2017-12-26 Tobira Therapeutics Inc processo de fabricação de cenicriviroc e análogos relacionados
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
SI3393468T1 (sl) 2015-12-22 2023-01-31 X4 Pharmaceuticals, Inc. Postopki za zdravljenje bolezni imunske pomanjkljivosti
CN109153722A (zh) 2016-04-08 2019-01-04 X4 制药有限公司 用于治疗癌症的方法
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN116554168A (zh) 2016-06-21 2023-08-08 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CA3028151A1 (en) 2016-06-21 2017-12-28 Tobira Therapeutics, Inc. Purified cenicriviroc and purified intermediates for making cenicriviroc
US10301287B2 (en) 2016-08-31 2019-05-28 Tobira Therapeutics, Inc. Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
EP3567028B1 (en) * 2016-12-09 2022-01-05 Medshine Discovery Inc. Biphenyl compound as ccr2/ccr5 receptor antagonist
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN113735904B (zh) * 2021-09-17 2023-10-24 南京自一界科技研发有限公司 一种润滑添加剂的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0769015B1 (en) 1994-07-04 2001-03-14 Takeda Chemical Industries, Ltd. Phosphonic acid compounds, their production and use
WO1999032468A1 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Anilide derivative, production and use thereof

Also Published As

Publication number Publication date
WO1999032100A2 (en) 1999-07-01
AU1683199A (en) 1999-07-12
JP2000128782A (ja) 2000-05-09
NO20003179D0 (no) 2000-06-19
US6268354B1 (en) 2001-07-31
WO1999032100A3 (en) 1999-09-10
BR9813691A (pt) 2000-10-10
CA2304959A1 (en) 1999-07-01
ID29994A (id) 2001-10-25
NO20003179L (no) 2000-06-19
EP1039899A2 (en) 2000-10-04
US6172061B1 (en) 2001-01-09
CN1282243A (zh) 2001-01-31
AU748064B2 (en) 2002-05-30
KR20010032841A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
HUP0100199A2 (hu) Anilid-származékot tartalmazó gyógyászati készítmény CCR5 antagonizálására
NO20003133D0 (no) Anilidderivater, fremstilling og anvendelse derav
HUP0100669A2 (hu) Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP0004400A2 (hu) Dipeptid-nitrilek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0103460A2 (hu) Vírusellenes hatású indolszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
HUP9802999A2 (hu) N-propargil-1-amino-indánt tartalmazó gyógyszerkészítmény
HUP0203766A2 (hu) 5-Piridil-1,3-azol vegyületek, ezek előállítási eljárása és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0000562A2 (hu) Kondenzált pirazolszármazékok, eljárás előállításukra, alkalmazásuk és az azokat tartalmazó gyógyszerkészítmények
MX9801716A (es) Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
HUP0101461A2 (hu) Új piridazinszármazékok és az azokat hatóanyagként tartalmazó gyógyszerkészítmények
MY119820A (en) Guanidine mimics as factor xa inhibitors
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
HUP0302435A2 (hu) 11-Béta-hidroxiszteroid dehidrogenáz 1 típusú enzimet gátló anyagok és ezeket tartalmazó gyógyszerkészítmények
IL123293A (en) Piperidine derivatives, their preparation and pharmaceutical compositions containing them
TR199801594A2 (xx) CCR-3 resept�r antagonistleri.
ATE202337T1 (de) Cyclopropylalkansäurederivate
HUP0301508A2 (hu) Antivirális hatású aza-indol-származékok és ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
HUP0202469A2 (hu) Sejt adhéziós inhibitor vegyület és ilyet tartalmazó gyógyszerkészítmény
HUP0102723A2 (hu) Új difenilkarbamid-származékok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények
HUP0002843A2 (hu) Új béta-karbolin-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
FR2712591B1 (fr) Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
NO305223B1 (no) Farmas°ytiske preparater med langsom frigivelse inneholdende nifedipin og fremgangsmÕte for fremstilling derav
HUP0001758A2 (hu) C-terminálison karbonil és heterociklusos funkciós csoportokkal rendelkező dolasztatin-15-származékok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk
HUP9801946A2 (hu) 5-HT-felvétel-inhibitorból és szelektív 5-H1A-antagonistából álló kombinációs gyógyászati készítmény és eljárás előállítására
HUP0001164A2 (hu) PF1022-ciklodepszipeptid-származékok